EGFR and neoplasm: Meanwhile, emerging data suggest that resistance to EGFR-TKIs may be also due to the activation of protein downstream of the receptor (K-RAS, mitogen-activated protein kinase, and signal transducers and activators of transcription 3), epithelial-mesenchymal transition of tumor cells, and other cell surface proteins, such as cMET [22–26].